Tillotts Pharma specialises in one area of therapy, diseases of the lower gastrointestinal tract.
The products that Tillotts is responsible for treat two disease conditions:

* inflammatory bowel disease (IBD)
* irritable bowel syndrome (IBS)

SALES & MARKETING
Tillotts markets two brands:

* Asacol®, which through the efforts of licensees and distributors has become the leading product worldwide for the treatment of Inflammatory Bowel Disease (IBD), consisting of Crohn's disease and ulcerative colitis, and
*
Colpermin®, a naturally based remedy for the treatment of symptoms of Irritable Bowel Syndrome (IBS).

5-ASA
Asacol
Colpermin
Crohn's disease
Epanova
IBD
IBS
Inflammatory bowel disease
Irritable bowel syndrome
Mesalazine
Peppermint oil
Tillotts
Ulcerative Colitis
Topasa

Tillotts is a small, fast growing pharmaceutical company based near Basel, in Switzerland.

  OUR BUSINESS  
     
 
  Tillotts Pharma AG, a Speciality Pharma company focusing on the Gastroenterology sector with presence in over 50 countries.

 

EXPERIENCED SALES & MARKETING TEAM AT TILLOTTS

Tillotts’ Sales and Marketing team comprises thirteen persons at this moment and is responsible for dealing with all commercial aspects of our network of distributors and direct sales operations, namely, screening medical literature and preparing digests; hosting scientific events, and attending key gastro meetings and congresses; maintaining a close liaison with the “top 20” distribution partners who are each visited yearly, some several times; carrying out promotional activities of all kinds; training of the distributors’ sales and marketing personnel as needed; organizing best practice sharing e. g. at annual meetings for distributors.

 

GROWTH STRATEGY

 

For more than a decade now Tillotts has enjoyed strong organic growth, achieving critical mass. By the 3rd quarter of 2009, more than two-thirds of the company’s sales were generated in European territories. From the period 2001 to 2008 Tillotts’ Asacol® sales have grown at a 12% compound annual growth rate out performing the growth of the entire IBD class.

 

The growth of the company’s sales are projected to further accelerate over the years to come due to following key strategic programs:

  • Continued market share growth of Asacol®
  • Expansion of Asacol® into new, attractive territories to extend global presence, such as Japan, Russia and many others
  • In-house development of product line extensions to Asacol® (details not disclosed)
  • Development of Next Generation Asacol® (details not disclosed)
  • In-licensing of complementary GI products
  • Outlicensing of Colpermin® and other pipeline products
  • Seek further co-operations for contract manufacturing

 

Asacol®, Colpermin®, Topasa® and Xenema® are Trade Marks or registered Trade Marks of Tillotts Pharma AG.

    
© 2007 by tillotts pharma ag – all rights reserved | designed by senger interactive
   photos: keystone science (visual center) | tillotts pharma ag